AI price cuts and the systems to stop AI── Price cuts, compute foundations, ways to stop AI, patient visits
Download the video (MP4, 11 MB)
The cost of using AI is falling fast. As it gets cheaper, it spreads quickly, into offices and into patients' hands. What worries me is this. Once it is everywhere, who notices a wrong answer and halts the work?
Today's events help with that question. They show why the fight over pricing is happening now. They show where the money behind cheaper use is flowing. And they show who is being asked to keep watch. For people in pharma, this is not a distant story. It reaches the budgets, contracts and patient data you handle every day.
01OpenAI's price cut
Source Stocktwits
We begin with what AI costs. Knowing why a provider charges less helps us read what comes next. Cheaper access may not be a gift. It may be a move in a contest.
| Who | What was reported |
|---|---|
| OpenAI | Explained a sharp cut in its prices |
| Michael Burry | Said the "real news" is preparing for DeepSeek V4 |
| DeepSeek | Expectations reported for its new V4 model |
Stocktwits report (10/11)
What stands out is a second reading of the move. The developer gave its own reasons. A well-known investor offered a different one, looking across the ocean at a rival. The idea is to set the terms early, before that rival ships its next product. In this view, the cut is a defensive step.
If that reading is right, a product nobody has seen is already moving a competitor's rates. That shows how fast this contest has become. The promise of a launch now matters more than the launch.
For pharma, the lesson is that today's rates may not last. Those rates can shift with a single move by a competitor. So I would keep contracts short, with clear review points. Locking in a long deal while it looks cheap can backfire. Starting small and growing step by step is the realistic path.
When costs fall, what grows? Next, we look at how cheap access widens usage, and where the money gathers.
02Cheaper AI, more demand
Source The Decoder ／ FourWeekMBA ／ BigGo Finance ／ The Times of India
When AI gets cheaper, how much more do people use? Knowing that lets you forecast your total spend.
Lower cost per use draws more users and more uses. Each call is cheaper, but the count rises, so the total grows. Some argue the biggest winner is the seller of the hardware.
When the billing unit gets cheaper, small jobs become worth sending to AI. Think of drafts or checks people used to do by hand. That is why volume climbs.
| Who | What was reported |
|---|---|
| NVIDIA | In talks to acquire Reflection AI (reported up to $25 billion) |
| Masayoshi Son | After investing $65 billion in OpenAI, seeking about $100 billion |
Huge sums are flowing to the firms that supply that volume. The chipmaker is said to be in talks to buy a model builder. A Japanese investor is reportedly seeking far more. This contest favors the deepest pockets.
This figure estimates how much of the world's planned computing one company could support. If one firm holds a large share, prices and supply follow its interests.
For a pharma budget, a lower unit cost does not mean lower spending. As more departments join, the company total swells. Decide early which work may use AI, and how much.
So does one hardware maker stay alone at the top? Next, we turn to the software layer that runs those machines.
03Tools to replace CUDA
Source https://tech-insider.org/
Beneath the low cost lies a hidden layer of software. Who builds that layer decides what choices users have. If only one exists, its owner sets the terms.
A developer and a large hardware maker from the same country have built tools for their own chips. The goal is to move away from a layer controlled by one overseas firm. Until now, running AI meant relying almost entirely on that layer. Now an alternative is starting to take shape.
This layer is the software that makes the chips do AI work. Without it, the hardware is hard to use. The leading firm's real strength lay here, more than in its chips. If rivals mature, that edge will wear down, and hardware prices will face pressure.
For pharma teams, this adds questions to vendor checks. Which country's stack runs the tool? Where does the data travel? Performance and cost are no longer enough. Patient data makes this even more serious. The cheaper the tool, the more its origin deserves a careful look.
The layer splits, and AI spreads even more cheaply. Then who holds the job of halting it?
04Calls for ways to stop AI
Source Yahoo Tech ／ Startup Fortune ／ CNBC ／ Firstpost
The wider AI spreads, the wider its mistakes reach. Now leaders of big AI makers are naming that danger themselves.
Emergency brake
Satya Nadella warned that AI is becoming an "insider risk" and called for an "emergency brake."
No reliance on one model
Nadella said no company should trust a single AI model, and that "we can't outsource responsibility."
Third-party evaluators
Independent bodies that assess AI safety from outside are reported to be gaining weight in the industry.
One big tech chief treats AI as a risky actor working within, not as an outside enemy. So a way to halt it must be designed in from the start. It reads as an admission that they cannot fully control it alone. The same leader warned against depending on any one system. Growing interest in outside safety checkers fits the same trend.
AI gains broad access as it takes on more work. When a trusted actor errs, the error is harder to spot than an outside attack. So AI needs managing like staff. With people, we set the scope of work and the reporting line first. AI needs the same order.
Pharma already has something close to this. Adverse event reports are collected and assessed, and use is halted when needed. Bring AI into operations the same way. Decide in advance who halts it, and when. Name the person who decides, and how that decision is recorded.
Yet away from company planning, people already lean on AI. Next, we look at patients.
05AI instead of a doctor's visit
Source Healthcare IT Today
One place where AI has become personal is checking symptoms. Why patients turn to it shapes the work of those who supply drug information.
| Behavior | Share |
|---|---|
| Have administered a self-test | 49% |
| Used an AI chatbot instead of seeing a doctor due to cost | 43% |
Healthcare IT Today headline (10/11). Survey design unknown
Look at the reason. Patients did not choose the bot for convenience. They chose it because a visit costs money. That answer was far from rare. Cost may be shifting the very entry point to care. Some people now stop at a chat and skip the clinic. Still, we do not know how the survey was built, so weigh the figures with care.
These tools give a plausible answer at once. But patients struggle to judge whether it is right. The bot's reply becomes the first explanation, before any physician. Even if it is wrong, the patient may arrive at the clinic believing it.
For pharma, this opens one more route by which drug information reaches patients. The accurate material we prepare may not be what gets used. Old or wrong content can spread through these tools. Publishing information in a form machines read correctly is becoming part of medical information work.
Yet the stories patients hear, and the ones we hear, contain much that nobody has checked.
06Claims not yet verified
Source Quartz ／ Startup Fortune ／ The Atlantic
Finally, who stands behind what is said about AI? As it spreads cheaply, talk without proof grows. The better a claim sounds, the sooner we should ask for evidence.
AI washing
The US Securities and Exchange Commission (SEC) warns companies about "AI washing," but reportedly rarely punishes them.
Others' API keys
DeepSeek's low-cost flash model was reported to have used other people's API keys. Details unconfirmed.
Literary prizes and AI
The Atlantic reported that another literary prizewinning work is suspected of being written by AI.
The doubts here differ in kind. One is inflated marketing. One is misuse of someone else's credentials. One is doubt about who really wrote a work. What they share is that outsiders struggle to check them. Regulators warn, but rarely act. Claims go unchallenged, and they multiply as AI spreads.
Simply carrying the label can make a product look more valuable. That is why exaggeration appears. While penalties stay weak, buyers must see through it themselves. The more a sales pitch leans on the label, the more questions you should prepare.
When a drug company buys an AI product, this doubt becomes its own problem. Test the vendor's claimed performance on your own tasks, and keep the records. That is routine in quality assurance. Apply it to AI. Judge by your own test results, not by the marketing.
The cheaper AI spreads, the more of the checking falls on users rather than builders.
Watch when DeepSeek V4 is released and how it affects OpenAI's pricing strategy.
Open the full transcript
Intro
The cost of using AI is falling fast. As it gets cheaper, it spreads quickly, into offices and into patients' hands. What worries me is this. Once it is everywhere, who notices a wrong answer and halts the work?
Today's events help with that question. They show why the fight over pricing is happening now. They show where the money behind cheaper use is flowing. And they show who is being asked to keep watch. For people in pharma, this is not a distant story. It reaches the budgets, contracts and patient data you handle every day.
CH 01 OpenAI's price cut
We begin with what AI costs. Knowing why a provider charges less helps us read what comes next. Cheaper access may not be a gift. It may be a move in a contest.What stands out is a second reading of the move. The developer gave its own reasons. A well-known investor offered a different one, looking across the ocean at a rival. The idea is to set the terms early, before that rival ships its next product. In this view, the cut is a defensive step.If that reading is right, a product nobody has seen is already moving a competitor's rates. That shows how fast this contest has become. The promise of a launch now matters more than the launch.For pharma, the lesson is that today's rates may not last. Those rates can shift with a single move by a competitor. So I would keep contracts short, with clear review points. Locking in a long deal while it looks cheap can backfire. Starting small and growing step by step is the realistic path. When costs fall, what grows?
Next, we look at how cheap access widens usage, and where the money gathers.
CH 02 Cheaper AI, more demand
When AI gets cheaper, how much more do people use?Knowing that lets you forecast your total spend.Lower cost per use draws more users and more uses. Each call is cheaper, but the count rises, so the total grows. Some argue the biggest winner is the seller of the hardware.When the billing unit gets cheaper, small jobs become worth sending to AI. Think of drafts or checks people used to do by hand. That is why volume climbs.Huge sums are flowing to the firms that supply that volume. The chipmaker is said to be in talks to buy a model builder. A Japanese investor is reportedly seeking far more. This contest favors the deepest pockets.This figure estimates how much of the world's planned computing one company could support. If one firm holds a large share, prices and supply follow its interests.For a pharma budget, a lower unit cost does not mean lower spending. As more departments join, the company total swells. Decide early which work may use AI, and how much. So does one hardware maker stay alone at the top?
Next, we turn to the software layer that runs those machines.
CH 03 Tools to replace CUDA
Beneath the low cost lies a hidden layer of software. Who builds that layer decides what choices users have. If only one exists, its owner sets the terms.A developer and a large hardware maker from the same country have built tools for their own chips. The goal is to move away from a layer controlled by one overseas firm. Until now, running AI meant relying almost entirely on that layer. Now an alternative is starting to take shape.This layer is the software that makes the chips do AI work. Without it, the hardware is hard to use. The leading firm's real strength lay here, more than in its chips. If rivals mature, that edge will wear down, and hardware prices will face pressure.For pharma teams, this adds questions to vendor checks. Which country's stack runs the tool?
Where does the data travel?Performance and cost are no longer enough. Patient data makes this even more serious. The cheaper the tool, the more its origin deserves a careful look. The layer splits, and AI spreads even more cheaply. Then who holds the job of halting it?
CH 04 Calls for ways to stop AI
The wider AI spreads, the wider its mistakes reach. Now leaders of big AI makers are naming that danger themselves.One big tech chief treats AI as a risky actor working within, not as an outside enemy. So a way to halt it must be designed in from the start. It reads as an admission that they cannot fully control it alone. The same leader warned against depending on any one system. Growing interest in outside safety checkers fits the same trend.AI gains broad access as it takes on more work. When a trusted actor errs, the error is harder to spot than an outside attack. So AI needs managing like staff. With people, we set the scope of work and the reporting line first. AI needs the same order.Pharma already has something close to this. Adverse event reports are collected and assessed, and use is halted when needed. Bring AI into operations the same way. Decide in advance who halts it, and when. Name the person who decides, and how that decision is recorded. Yet away from company planning, people already lean on AI. Next, we look at patients.
CH 05 AI instead of a doctor's visit
One place where AI has become personal is checking symptoms. Why patients turn to it shapes the work of those who supply drug information.Look at the reason. Patients did not choose the bot for convenience. They chose it because a visit costs money. That answer was far from rare. Cost may be shifting the very entry point to care. Some people now stop at a chat and skip the clinic. Still, we do not know how the survey was built, so weigh the figures with care.These tools give a plausible answer at once. But patients struggle to judge whether it is right. The bot's reply becomes the first explanation, before any physician. Even if it is wrong, the patient may arrive at the clinic believing it.For pharma, this opens one more route by which drug information reaches patients. The accurate material we prepare may not be what gets used. Old or wrong content can spread through these tools. Publishing information in a form machines read correctly is becoming part of medical information work. Yet the stories patients hear, and the ones we hear, contain much that nobody has checked.
CH 06 Claims not yet verified
Finally, who stands behind what is said about AI?As it spreads cheaply, talk without proof grows. The better a claim sounds, the sooner we should ask for evidence.The doubts here differ in kind. One is inflated marketing. One is misuse of someone else's credentials. One is doubt about who really wrote a work. What they share is that outsiders struggle to check them. Regulators warn, but rarely act. Claims go unchallenged, and they multiply as AI spreads.Simply carrying the label can make a product look more valuable. That is why exaggeration appears. While penalties stay weak, buyers must see through it themselves. The more a sales pitch leans on the label, the more questions you should prepare.When a drug company buys an AI product, this doubt becomes its own problem. Test the vendor's claimed performance on your own tasks, and keep the records. That is routine in quality assurance. Apply it to AI. Judge by your own test results, not by the marketing. The cheaper AI spreads, the more of the checking falls on users rather than builders.
Wrap-up
The fight over pricing is putting AI within everyone's reach. But as it gets cheaper, the duty to watch and verify shifts to users. The habit pharma teams already have, pausing to check, fits this moment. Tomorrow, we watch the next step by the rival behind these moves. That step should clarify what today's cuts mean.
- CH 01Stocktwits「OpenAI Explains Why It's Slashing AI Prices — Michael Burry Says The 'Real News' Is Preparation For DeepSeek's New V4 Models」 stocktwits.com
- CH 02The Decoder「Cheaper AI tokens are driving more demand, and that's Jensen Huang's best-case scenario」 the-decoder.com
- CH 02FourWeekMBA「SemiAnalysis: Nvidia Could Back 46 GW of a 240 GW AI Build」 fourweekmba.com
- CH 02BigGo Finance「Nvidia Weighs Deeper Stake or Full Takeover of AI Startup Reflection」 finance.biggo.com
- CH 02The Times of India「After investing $65 billion in Sam Altman's OpenAl, Japan's richest man Masayoshi Son is seeking $100 bil」 timesofindia.indiatimes.com
- CH 03https://tech-insider.org/「DeepSeek, Huawei Ship 6 Ascend Tools to Rival CUDA [2026]」 tech-insider.org
- CH 04Yahoo Tech「Microsoft's Satya Nadella Warns AI Is Becoming An ‘Insider Risk’, Calls For 'Emergency Brakes' — ‘We Can’t Outsource Responsibility’」 tech.yahoo.com
- CH 04Startup Fortune「Satya Nadella says no company should trust a single AI model」 startupfortune.com
- CH 04CNBC「AI’s quiet safety gatekeepers are stepping into the spotlight」 cnbc.com
- CH 04Firstpost「Independent AI evaluators gain importance as debate over safety and regulation grows」 firstpost.com
- CH 05Healthcare IT Today「Bonus Features – October 11, 2026 – 49% of patients have administered a self-test, 43% have used an AI chatbot instead of seeing a doctor because of cost concerns, plus 30 more stories」 healthcareittoday.com
- CH 06Quartz「The SEC warns companies about 'AI washing' but rarely punishes them」 qz.com
- CH 06Startup Fortune「DeepSeek's cheap flash model reportedly spent other people's API keys」 startupfortune.com
- CH 06The Atlantic「Yet Another Literary Prizewinner Seems to Be AI」 theatlantic.com
Articles used
Today's related reports
- AI Daily News October 12, 2026
- AI & Economy News October 12, 2026
- AI & Finance News October 12, 2026
The narration is synthetic speech. The content draws only on this site's articles from the same day. Each edition passes seven plain-language checks before publication. That means known obstacles to comprehension are held below threshold — it is not a guarantee of comprehension.